Norwich Clinical Services is expected to offer a complete range of clinical research capabilities including Phase I – IV trials, bioanalytical studies and pharmacovigilance monitoring services. Norwich Clinical
Mr Russell will report to John Chiminski, president and CEO of Catalent, and will be based in Catalent’s Philadelphia packaging facility. David Heyens, the current incumbent, will simultaneously
Ipsen has posted drug sales of EUR258m, an increase of 6.3%, compared to EUR242.8m for the year ago period. This performance was driven by strong specialty care sales,
As per the terms of the licensing and supply agreement, Par Pharmaceutical has made a payment to Glenmark for exclusive rights to commercialise Ezetimibe in the US. The
As per the terms of the agreement, Perrigo acquired 100% of the shares of PBM Holdings for $808m in cash. Pursuant to the agreement, Perrigo and PBM expect
Cimzia is indicated for reducing the signs and symptoms of Crohn’s disease and maintaining clinical response in adult patients with moderately to severely active disease who have had
Immucor claimed that NEO is designed to increase productivity, performance and flexibility of high volume laboratories. NEO delivers type-and-screen throughput and broadest test menu as well as new
Automaglia 90 Analyzer is a fully-automated analyzer for immunoassay analysis in various types of diseases and disorders. Major clinical diagnostic applications include thyroid disorders, fertility and infertility disorders,
The grant is expected to be used to fund the study of mechanisms of cellular reprogramming with the specific aim of enhancing the efficiency of reprogramming techniques. Through
As per the terms of the agreement, Protox is expected to receive an upfront payment of $3m and is eligible to receive a near term milestone payment of
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.